Department of Thoracic Surgery, Wuxi 9th People's Hospital affiliated to Soochow University, Wuxi, Jiangsu, China.
Department of Neurosurgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Cancer Med. 2021 Jun;10(12):4017-4029. doi: 10.1002/cam4.3945. Epub 2021 May 15.
Lung squamous cell carcinoma (LUSC), one of the main types of lung cancer, has caused a huge social burden. There has been no significant progress in its therapy in recent years, Resulting in a poor prognosis. This study aims to develop a glycolysis-related gene signature to predict patients' survival with LUSC and explore new therapeutic targets.
We obtained the mRNA expression and clinical information of 550 patients with LUSC from the Cancer Genome Atlas (TCGA) database. Glycolysis genes were identified by Gene Set Enrichment Analysis (GSEA). The glycolysis-related gene signature was established using the Cox regression analysis.
We developed five glycolysis-related genes signature (HKDC1, AGL, ALDH7A1, SLC16A3, and MIOX) to calculate each patient's risk score. According to the risk score, patients were divided into high- and low-risk groups and exhibited significant differences in overall survival (OS) between the two groups. The ROC curves showed that the AUC was 0.707 for the training cohort and 0.651 for the validation cohort. Additionally, the risk score was confirmed as an independent risk factor for LUSC patients by Cox regression analysis.
We built a gene signature to clarify the connection between glycolysis and LUSC. This model performs well in evaluating patients' survival with LUSC and provides new biomarkers for targeted therapy.
肺鳞状细胞癌（LUSC）是肺癌的主要类型之一，给社会造成了巨大的负担。近年来，其治疗方法没有显著进展，导致预后较差。本研究旨在建立一个与糖酵解相关的基因特征，以预测 LUSC 患者的生存情况，并探索新的治疗靶点。
我们从癌症基因组图谱（TCGA）数据库中获得了 550 名 LUSC 患者的 mRNA 表达和临床信息。通过基因集富集分析（GSEA）确定糖酵解基因。使用 Cox 回归分析建立与糖酵解相关的基因特征。
我们开发了五个与糖酵解相关的基因特征（HKDC1、AGL、ALDH7A1、SLC16A3 和 MIOX）来计算每个患者的风险评分。根据风险评分，患者被分为高风险组和低风险组，两组之间的总生存期（OS）存在显著差异。ROC 曲线显示，训练队列的 AUC 为 0.707，验证队列的 AUC 为 0.651。此外，Cox 回归分析证实风险评分是 LUSC 患者的独立预后因素。
我们构建了一个基因特征，以阐明糖酵解与 LUSC 之间的关系。该模型在评估 LUSC 患者的生存情况方面表现良好，并为靶向治疗提供了新的生物标志物。
